Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Colorcon
Medtronic
Moodys
McKinsey

Last Updated: August 17, 2022

ZYVOX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Zyvox patents expire, and what generic alternatives are available?

Zyvox is a drug marketed by Pfizer and is included in three NDAs.

The generic ingredient in ZYVOX is linezolid. There are twenty-two drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the linezolid profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Zyvox

A generic version of ZYVOX was approved as linezolid by TEVA PHARMS on June 27th, 2012.

  Try it Free

Paragraph IV (Patent) Challenges for ZYVOX
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZYVOX Injection linezolid 2 mg/mL, 100 mL bag 021131 1 2009-12-29
ZYVOX Injection linezolid 2 mg/mL, 300 mL bag 021131 1 2009-09-01
ZYVOX Oral Suspension linezolid 100 mg/5 mL 021132 1 2009-08-03
ZYVOX Tablets linezolid 600 mg 021130 1 2005-12-21

US Patents and Regulatory Information for ZYVOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer ZYVOX linezolid FOR SUSPENSION;ORAL 021132-001 Apr 18, 2000 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer ZYVOX linezolid SOLUTION;INTRAVENOUS 021131-003 Apr 18, 2000 AP RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Pfizer ZYVOX linezolid SOLUTION;INTRAVENOUS 021131-001 Apr 18, 2000 AP RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ZYVOX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer ZYVOX linezolid SOLUTION;INTRAVENOUS 021131-003 Apr 18, 2000 See Plans and Pricing See Plans and Pricing
Pfizer ZYVOX linezolid FOR SUSPENSION;ORAL 021132-001 Apr 18, 2000 See Plans and Pricing See Plans and Pricing
Pfizer ZYVOX linezolid TABLET;ORAL 021130-001 Apr 18, 2000 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ZYVOX

See the table below for patents covering ZYVOX around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 0170225 See Plans and Pricing
European Patent Office 1265608 FORMULATION DE TABLETTE A BASE D'OXAZOLIDINONE (OXAZOLIDINONE TABLET FORMULATION) See Plans and Pricing
Japan 3176630 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ZYVOX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0717738 PA2004004,C0717738 Lithuania See Plans and Pricing PRODUCT NAME: LINEZOLIDUM ((S)-N-((3-(3-FLUOR-4-(4-MORFOLINIL)FENIL)-2-OKSO--5-OKSAZOLIDINIL)METIL)-ACETAMIDAS); REGISTRATION NO/DATE: 02/8199/2 20030313
0717738 CA 2002 00004 Denmark See Plans and Pricing
0717738 SPC001/2002 Ireland See Plans and Pricing SPC001/2002: 20031204, EXPIRES: 20160104
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Dow
Express Scripts
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.